{'fraction_non_alphanumeric': 0.023148148148148147, 'fraction_numerical': 0.005401234567901234, 'mean_word_length': 5.00462962962963, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Continuous blood glucose monitoring with feedback-controlled glucose infusion during surgical management of insulinoma: report of a case.

Perioperative management of insulinoma may be facilitated by the use of a glucose-controlled insulin infusion system (GCIIS; Biostator System, Miles Laboratories Inc., Elkhart, Ind.). We monitored the blood glucose levels and glucose infusion rates before, during and after surgery in a 35-year-old woman with insulinoma. After an overnight fast, glucose was infused according to a preset program and maintained the blood glucose level at around 50 mg/dl. Depression of the blood glucose level and simultaneous elevation of the glucose infusion rate were noted when the tumor was massaged. A sharp decrease in the glucose infusion rate occurred almost immediately after removal of the tumor. It took about 4 minutes for the blood glucose to go up to a level of 90 mg/dl. These results demonstrate the usefulness of GCIIS not only in maintaining stationary blood glucose, but also in localizing the tumor and in providing evidence of complete removal of the tumor. When the infusion system is programmed appropriately, the glucose infusion rate, as compared to the blood glucose level, reacts more quickly and sensitively to sudden changes in insulin levels.